1-3 of 3
Yanni Zhang
Close
Sort by
Journal Articles

Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)

Zhijian Xiao, Chunkang Chang, Qiubai Li, Xiaojing Yan, Tiejun Qin, Hongyan Tong, Yu Zhang, Min Dai, Yanjie He, Jianyu Weng, Jian Li, Sujun Gao, Rong Fu, Xudong Wei, Aili He, Jinhai Ren, Tong Wu, Xin Du, Yanni Zhang, Ke Xu, Zhengyi Wang, Michelle Yang, Andrew Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 8821–8822.
https://doi.org/10.1182/blood-2022-163880
Published: 2022
Journal Articles

Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in Relapsed or Refractory Multiple Myeloma (rrMM) and the Correlation with CD47 and CD38 Expression

Yanni Zhang, Zhen Sheng, Jie Xia, Chunyan Ye, Yan Liu, Zhengyi Wang, John Hayslip, Andrew Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 9937–9938.
https://doi.org/10.1182/blood-2022-164755
Published: 2022
Journal Articles

A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results

Junyuan Qi, MD, Jian Li, MD, Bin Jiang, MD, Bo Jiang, MD, Hongzhong Liu, MD, Xinxin Cao, MD, Meixiang Zhang, MD, Yuan Meng, MD, Xiaoyu MA, Yingmin Jia, Jiyuan Guo, Yanni Zhang, Wei Huang, Jianxiang Wang, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-134391
Published: 2020